The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)
FOCUS ARTICLE - WILL THIS TRIAL CHANGE MY PRACTICE?
The SURTAVI study: TAVI for patients with intermediate risk
EuroIntervention 2017;13:e617-e620 published online e-edition August 2017. DOI: 10.4244/EIJV13I5A97
Daniel A. Jones1*, MBBS, PhD; Didier Tchétché2, MD; John Forrest3, MD; Farrel Hellig4, BSc, MBBCh, FCP(SA), FSCAI; Alexandra Lansky5, MD; Neil Moat6, MBBS
1. Department of Cardiology, Barts Heart Centre, London, United Kingdom; 2. Department of Interventional Cardiology, Clinique Pasteur, Toulouse, France; 3. Division of Cardiology, Yale School of Medicine, New Haven, CT, USA; 4. Department of Cardiology, S
Introduction to the session: the trial headlines
The aim of this article is to capture the session at EuroPCR 2017 covering the SURTAVI study, communicate the analysis of the trialists, and report the views expressed in the interactive discussion. This article does not constitute an independent review of the topic by the authors.
The SURTAVI study (Safety and Efficacy of the CoreValve® System in the Treatment of Severe, Symptomatic Aortic Stenosis in Intermediate Risk Subjects Who Need Aortic Valve Replacement)1 was the focus of the discussion during the dedicated session at EuroPCR 2017 entitled “Will this trial change my ...